Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conference
New clinical data for bizaxofusp, used for the treatment of unresectable recurrent IDH-WT glioblastoma, a uniformly fatal form of brain cancer, will also be presented during an oral session at an upcoming medical conference
Enrolment in the Phase 1/2 ABILITY-1 study remains on track for completion in Q3 2026; Medicenna plans to explore with regulators on a potential expedited registrational development path
NEO-CYT continues to enrol patients with melanoma in a randomized Phase 1b study evaluating MDNA11 in combination with nivolumab ± ipilimumab prior to surgery
A welcome email is on its way. If you don't see it, please check your junk folder.
Planning is underway for an IND submission with a Phase 1 trial commencing in 2027 for Medicenna’s first-in-class targeted and conditionally activated bifunctional anti-PD-1-IL-2
TORONTO and HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune, and inflammatory diseases, today reported financial results for the three months ended June 30, 2026 and provided a corporate update.
“We are delighted to have the opportunity to present new clinical data at oral sessions at two major upcoming medical conferences for our most advanced pipeline candidates, MDNA11 and bizaxofusp,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “During the first quarter, we continued to execute against the milestones we outlined earlier this year, and our key programs remain on track. Completion of enrolment in ABILITY-1 is expected this quarter, with updated MDNA11 clinical results to be provided during an oral presentation at an upcoming conference and to explore with regulators on a potential expedited registrational development path. We also look forward to presenting new clinical data on bizaxofusp in an oral session at an upcoming conference. While NEO-CYT continues to enrol at multiple centres in Italy, we continue to advance MDNA113 to support an IND submission with plans to commence a first-in-human study in 2027. We look forward to a data-rich period during the remainder of this year.”
Program highlights for the three months ended June 30, 2026, along with recent developments, include:
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.
